Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Real-time Estimate Cboe BZX
Other stock markets
 10:18:19 2024-04-16 am EDT 		5-day change 1st Jan Change
126.4 USD +0.15% Intraday chart for Merck & Co., Inc. -0.36% +15.81%
Apr. 15 Zacks Adjusts Price Target on Merck & Company to $132 From $128 MT
Apr. 11 Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zacks Adjusts Price Target on Merck & Company to $132 From $128
MT
Moderna cancer vaccine shows promise in initial tests; share skyrockets
AQ
Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust
CI
Merck & Co Receives a Shareholder Proposal from National Legal and Policy Center
CI
Merck & Co Receives a Shareholder Proposal from Kenneth Steiner
CI
Transcript : Merck & Co., Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024 09:55 AM
S&P 500 ends slightly higher as markets brace for inflation data, earnings
RE
Wall St backs down as markets brace for inflation data, earnings
RE
Moderna Shares Rise Following Positive Results of Head and Neck Cancer Vaccine in Early Study
MT
Moderna jumps as personalized cancer vaccine shows benefit in early study
RE
Berenberg Raises Price Target on Merck & Company to $143 From $140, Maintains Buy Rating
MT
Geneos cancer vaccine shrinks liver tumors in small trial
RE
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer
AQ
Boehringer to lay off salespeople as Humira biosimilar sales lag
RE
Boehringer to lay off salespeople as Humira biosimilar sales lag
RE
Merck & Co., Inc. acquired Abceutics, Inc. for approximately $210 million.
CI
Merck Starts Phase 3 Clinical Trial of Potential Lung Cancer Combination Therapy
MT
Merck: launches phase III trial in lung cancer
CF
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
BU
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.